Kymera Therapeutics Inc
(NAS:KYMR)
$
50.05
-1.84 (-3.55%)
Market Cap: 3.24 Bil
Enterprise Value: 2.90 Bil
PE Ratio: 0
PB Ratio: 3.63
GF Score: 47/100 Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 08:15PM GMT
Release Date Price:
$18.99
(-0.47%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
All right. Welcome, everyone. This is the fireside chat with Kymera Therapeutics. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley research team. Before we get started, I need to read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please see -- please reach out, excuse me, to your Morgan Stanley sales representative.
With that, very happy to have with me Nello and Jared from the Kymera team. Thank you both for joining us.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thank you.
Jared A. Gollob;Vikram Purohit
Kymera Therapeutics, Inc. - Chief Medical Officer;Morgan Stanley, Research
Yes. Thanks, Vikram.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot